GlobeNewswire 12-26 Fitell Corporation Announces Interim Dividend and Shareholder Loyalty Program
GlobeNewswire 12-17 VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement 
GlobeNewswire 12-15 CRML Announces Another Set of Outstanding Rare Earth Elements Results From Its 2024 Drilling Program...
GlobeNewswire 12-15 Fitell Corporation Unveils 2FCulinary AI, its first AI-Driven Personal Robot Chef for Personalized M...
GlobeNewswire 12-11 Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 202...
GlobeNewswire 12-11 Lantronix Expands Presence in Global Drone and Defense Markets with Trillium Engineering Collaborati...
Newsfile Corp 12-11 Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing
GlobeNewswire 12-02 Fitell Corporation Announces Interim Dividend and Shareholder Loyalty Program
GlobeNewswire 12-02 Goliath Reports 10 High-Grade Holes Up To 7.28 g/t Au Over 8.00 Meters Within 5.85 g/t Au Over 10.00...
GlobeNewswire 12-01 Fitell Corporation Announces $3 Million Share Repurchase Program
GlobeNewswire 11-18 Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Di...
GlobeNewswire 11-17 Fitell Corporation Announces Fiscal Year 2025 Results
GlobeNewswire 11-17 Goliath Drills Several Holes Of High-Grade Gold Up To 10.25 g/t Au Over 7.02 Meters Within 5.20 g/t ...
GlobeNewswire 11-13 Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire 11-13 Goliath Resources Discloses Observations In Holes From This Years Exploration Campaign On The Surebe...
GlobeNewswire 11-12 Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire 11-11 AMD Unveils Strategy to Lead the $1 Trillion Compute Market and Accelerate Next Phase of Growth
GlobeNewswire 11-10 Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended Sep...
GlobeNewswire 11-10 Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Busi...
GlobeNewswire 11-08 Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Stud...
GlobeNewswire 11-08 Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 a...
GlobeNewswire 11-08 Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Pro...
GlobeNewswire 11-06 Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented ...
GlobeNewswire 11-05 Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
GlobeNewswire 11-05 Royalty Pharma Reports Third Quarter 2025 Results